Inhibitors of insulin-like growth factor-1 receptor tyrosine kinase are preferentially cytotoxic to nutrient-deprived pancreatic cancer cells
- PMID: 19166817
- DOI: 10.1016/j.bbrc.2009.01.065
Inhibitors of insulin-like growth factor-1 receptor tyrosine kinase are preferentially cytotoxic to nutrient-deprived pancreatic cancer cells
Abstract
Chronic deprivation of nutrients is rare in normal tissues, however large areas of tumor are nutrient-starved and hypoxic due to a disorganized vascular system. Some cancers show an inherent ability to tolerate severe growth conditions. Therefore, we screened chemical compounds to identify cytotoxic agents that function preferentially in nutrient-deprived conditions. We found that AG1024, a specific inhibitor of insulin-like growth factor-1 receptor tyrosine kinase (IGF-1R), showed preferential cytotoxicity to human pancreatic cancer cells in nutrient-deprived conditions relative to cells in nutrient-sufficient conditions. The cytotoxicity of I-OMe-AG538 (another specific inhibitor of IGF-1R kinase) was also enhanced in nutrient-deprived cells. In addition, AG1024 and I-OMe-AG538 potently inhibited IGF-1R activation to nutrient-deprived cells. In contrast, conventional chemotherapeutic drugs, as well as inhibitors of PDGFR and EGFR kinases, elicited weak cytotoxicity. These data indicate that nutrient-deprived human pancreatic cancer cells have increased sensitivity to inhibition of IGF-1R activation. IGF-1R inhibitors offer a promising strategy for anticancer therapeutic approaches that are oriented toward tumor microenvironment.
Similar articles
-
Mitochondrial inhibitors show preferential cytotoxicity to human pancreatic cancer PANC-1 cells under glucose-deprived conditions.Biochem Biophys Res Commun. 2010 Feb 12;392(3):460-6. doi: 10.1016/j.bbrc.2010.01.050. Epub 2010 Jan 18. Biochem Biophys Res Commun. 2010. PMID: 20083087
-
Tumor-targeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment.J Control Release. 2012 Apr 30;159(2):281-9. doi: 10.1016/j.jconrel.2011.12.027. Epub 2011 Dec 29. J Control Release. 2012. PMID: 22227023
-
Comparison of three approaches for inhibiting insulin-like growth factor I receptor and their effects on NSCLC cell lines in vitro.Growth Factors. 2007 Feb;25(1):1-8. doi: 10.1080/08977190600702865. Growth Factors. 2007. PMID: 17454144
-
The insulin-like growth factor 1 receptor in cancer: old focus, new future.Eur J Cancer. 2007 Sep;43(13):1895-904. doi: 10.1016/j.ejca.2007.05.021. Epub 2007 Jul 10. Eur J Cancer. 2007. PMID: 17624760 Review.
-
The insulin like growth factor-1 receptor (IGF-1R) as a drug target: novel approaches to cancer therapy.Growth Horm IGF Res. 2004 Aug;14(4):287-95. doi: 10.1016/j.ghir.2004.02.004. Growth Horm IGF Res. 2004. PMID: 15231297 Review.
Cited by
-
Type I insulin-like growth factor receptor signaling in hematological malignancies.Oncotarget. 2017 Jan 3;8(1):1814-1844. doi: 10.18632/oncotarget.12123. Oncotarget. 2017. PMID: 27661006 Free PMC article. Review.
-
Structural and Functional Characterization of Rv0792c from Mycobacterium tuberculosis: Identifying Small Molecule Inhibitor against HutC Protein.Microbiol Spectr. 2023 Feb 14;11(1):e0197322. doi: 10.1128/spectrum.01973-22. Epub 2022 Dec 12. Microbiol Spectr. 2023. PMID: 36507689 Free PMC article.
-
Insulin-like growth factor-1 receptor regulates repair of ultraviolet B-induced DNA damage in human keratinocytes in vivo.Mol Oncol. 2016 Oct;10(8):1245-54. doi: 10.1016/j.molonc.2016.06.002. Epub 2016 Jun 16. Mol Oncol. 2016. PMID: 27373487 Free PMC article.
-
Risk factors and therapeutic targets in pancreatic cancer.Front Oncol. 2013 Nov 18;3:282. doi: 10.3389/fonc.2013.00282. Front Oncol. 2013. PMID: 24303367 Free PMC article. Review.
-
The IGF-II-Insulin Receptor Isoform-A Autocrine Signal in Cancer: Actionable Perspectives.Cancers (Basel). 2020 Feb 5;12(2):366. doi: 10.3390/cancers12020366. Cancers (Basel). 2020. PMID: 32033443 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous